Vai trò của thuốc chống đông thế hệ mới trong bệnh lý mạch vành có gì mới năm 2014

!"#$%&'$()"$%*+,($(*, $/0 $%*1$
*2$34#$/,#$5 4#$!"#$%!&'($)*'!$%+,$
!"#$"#%&'()*+%&',-%.(/+'0%12"330%1"324%
Bộ#môn#Tim#mạch#–#Trường#Đại#học#Y#Hà#Nội#
Đơn#vị#Chăm#sóc#Mạch#vành#–#Viện#Tim#mạch#Việt#Nam#
Chương#trình#Phòng#Chống#Tăng#huyết#áp#Quốc#gia#
Email:###
Hội#chứng#vành#cấp#
không#có#ST#chênh#lên#
##Hội#chứng#vành#cấp##
có#ST#chênh#lên#
6#7+$.8$9:;$&"$%<#$3<(*$5=-*$%*)$>*<3?$
55%
67%
89%
87%
:%
5%
9%
89%
;9%
59%
<9%
=>?%@AB%CADE%% ?F%@GH%IAJ-% &AKL(%MF%@GH%
&>3!%-NC%O+P688Q%
$R+A%=>?%S+%TF+A%O+P66UQ%
V%
WX9#996%
WX9#99<% WX9#99;%
'($/0$12$345$6#7%8439.'$:;;<=>>;?@:ABCC5$
@A%$3: $9B$5C"$6D!$E$-*#7+$5F$%&GH$

DE$27F$'&2$GH'($IJ$)K3$LMDNO$%H$C$P/DQ$27.'($R/6S$%+,$)*$TU'!$P/D$V'$WE'!$
I#1-$(,$9:;$&"$%&J-$-*#7+$5F$%&G$9B$5C"$6D!$
O2.'1$XY$12$345$R$Z'(4$[$/1\$:;>>=C]<?::]B:C^5$
S#G1B2.BZ)1'2$687)1_$`.7$/a6Z$3b17$O8%%1__`84c$N'%.G,4#%321\$d6M$#'$a6O$
R3823$OSc$12$345$de.O$f'1$:;>>=]?1:]@>g$
KLMDN$ @KLMDN$
Y/)Z%
Y/)Z%
)[/GZ%
)[/GZ%
@.+;$(B$OP+$Q=#$R"+$*S#$(*A $5=-*$(T>$
LU$5V $R"+$*S#$(*A $5=-*$(T>$
7%
5%
:%
;%
U%
8%
6%
9%
LW$O2$%U$5V $X(*$OY;$Z[\$
@.=;$]^$%_$]*#$-*`>$5#2-$
65% 85% U5% ;5% :5% 55% 75% <5% \5% 695%665%685%6U5%6;5%6:5%655%675%6<5%
KL$]*0 $
9a($/F-*$
KL$(*J-*$
9+, $
KL$(*J-*$
OJ-$$
/3'\14hi1#($ec$12$345$Z87$-1372$[$:;;]=:g?::A^j@C5$

k.I$0ac$12$345$Z87$-1372$[$:;>;=C>?:g^^j]<5$
lK$4#U8$_V$T"$Xma6Z$LQ$
U9%+'])%%
%
U#;V%%
%
5#;V%
%
%
<#:V%
6%+^E%
%
88V%%
%
6\V%
%
%
6<V%
Khoảng#5%#tử#vong#trong#30#ngày,#
20%#tử#vong#sau#5#năm#
!_%M`+'%%
European#data#
2004#
N=#6385#
N#=#46829%
k.I$0$12$345$Z87$-1372$[c$:;>;=$C>?:g^^B]<5$
I#1-$(,$b3$ 3<(*$R"+$*S#$(*A $5=-*$(T>$
cdef[$(g$h$c$@DiL$
fef[$(g$h$c$LIDD@$
jkel[$(g$h$c-*`>$5#2-$QV$*m($5=-*$(T>$

@A%$OVn%$3: $9B$5C"$
o8-*$%*=-*$*+;1%$]*,#$$
Lp($3<(*$/V<-$9"$
q*g $%*G(*$Kr&V%V-#-$
iV$%*p%$3<(*$
Lp($ *s-$(B$*t($
iB$*t($ oVa$*t($
!Ka(%-b(%Tc+'%M/K%@Gd%@G(+'%@eE%
@G`+'%fR+A%ED-A%M]+A%-NC%
f7T1$[5$S!7.GT$-31G._2$:;;A=@@?CA:jAg5$
o8-*$%*=-*$%*&V3u#-$%&V $viK$
a7\#__#'.$l$12$345$n4 \$:;;C=>;:?:gC>j:gC^5$
iV".+O"bV-$v(b5"bV-$wV x%r&3$vyr&$viK$$
!G$%&G$%a($/S $()"$%*+,($]*a $/0 m]*a $b^+$(z+$
Events/

patient-years"
Study, year"
Rate ratio

(95% CI)"
Weight
(%)"
Warfarin" ASA"
ATACS pilot, 1990" 0.22 (0.01 – 4.66)" "0.5" 0/9" 1/7"
ATACS main, 1994" 0.69 (0.29 – 1.65)" "5.7" 6/24" 9/25"
Williams et al., 1997" 0.19 (0.03 – 1.16)" "1.3" 1/6" 5/5"
APRICOT–2, 2002" 0.28 (0.09 – 0.92)" "3.1" 3/34" 11/35"
OASIS main, 2001" 0.58 (0.38 – 0.98)" "23.9" 30/373" 52/375"
OASIS pilot, 1998" 0.51 (0.20 – 1.26)" "5.2" 5/25" 10/25"
Huynh et al., 2001" 2.07 (0.20 – 21.85)" "0.8" 2/38" 1/39"
ASPECT–2, 2002" 0.69 (0.31 – 1.53)" "6.8" 10/298" 14/289"

Zibaeenezhad et al., 2004" 0.87 (0.20 – 2.28)" "2.9" 4/70" 6/70"
WARIS II, 2002" 0.56 (0.42 – 0.75)" "49.8" 69/4,927" 117/4,669"
Overall" 0.56 (0.48 – 0.69)" "100.0" 130/5,834"228/5,539"
Meta-analysis of anticoagulation: efficacy
Prevent 19 MIs per 1,000 pt-years
0.05"
Favours warfarin"
1.0"
Rate

ratio"
5.0"
Favours ASA"
Rothberg MB, et al. Ann Int Med. 2005;143:241-250.
Recurrent MI
Events/

patient-years"
Study, year"
Rate ratio

(95% CI)"
Weight
(%)"
Warfarin" ASA"
ATACS main, 1994" 7.26 (0.39 – 33.50)" "1.8" 3/24" 0/25"
Williams et al., 1997" 2.91 (0.14 – 59.06)" "1.7" 1/6" 0/5"
APRICOT–2, 2002" 1.03 (0.15 – 6.90)" "4.3" 2/34" 2/35"
OASIS main, 2001" 2.20 (1.24 – 3.90)" "47.4" 35/373" 16/375"
OASIS pilot, 1998" 2.02 (0.20 – 20.86)" "2.9" 2/25" 1/25"
Huynh et al., 2001" 5.16 (0.26 – 104.09)" "1.7" 2/38" 0/39"
ASPECT–2, 2002" 2.26 (0.59 – 8.67)" "8.7" 7/298" 3/289"
Zibaeenezhad et al., 2004" 2.50 (0.50 – 12.46)" "6.1" 5/70" 2/70"

WARIS II, 2002" 3.32 (1.51 – 7.27)" "25.4" 28/4,927" 8/4,669"
ATACS pilot, 1990" Excluded" 0/9" 0/7"
Overall" 2.48 (1.67 – 3.68)" "100.0" 85/5,804" 32/5,539"
Meta-analysis of anticoagulation: safety
“Major” bleeding
Increase 9 bleeds per 1,000 pt-years
0.05"
Favours warfarin"
1.0"
Rate

ratio"
5.0"
Favours ASA"
Rothberg MB, et al. Ann Int Med. 2005;143:241-250.
16
32
40
0
5
10
15
20
25
30
35
40
45
Aspirin
(n =
1,206)

Warfarin
(n =
1,216)
ASA +
warfarin
(n =
1,208)
Withdrawal from treatment (%)
WARIS II and OASIS–2:
Compliance with warfarin post ACS
8.9
9
6.1
7.8
0
1
2
3
4
5
6
7
8
9
10
Good
complier
countries
Poor
complier

countries
Patients with CVD, MI, CVA (%)
Standard therapy OAC
P = 0.33 P = 0.02
WARIS II OASIS–2
Hurlen M, et al. N Engl J Med. 2002;347:969-974.
The OASIS Investigators. J Am Coll Cardiol. 2001;37:475-484.
f4\(71'$[$12$345$Z87$-1372$[c$:;>C=C<?>]g;jA;$
7%g3!Z0%U6999%+'hiK%fR+A%
6UV%/ZCKGK+0%<7V%j2W!%
X#HG$T#o'$%p$9G$Gq%!$%!F'!$$
O@_%M`+'%Y`%kE%ED-A0%&>3!0%!$>&Q%
2ZCKGK+l %mg%9#79%O9#:\n9#<;Q%
j2W!l%% %mg%9#<7%O9#<9n9#\:Q%
Sr'($T#o'$%p$%!Hs$Gt8$
2ZCKGK+l %mg%6#7\%O6#:;n8#9\Q%
j2W!l % %mg%8#U;%O8#95n8#55Q%
0o2$48u'$$
•  oKpE%+Aq%fKr+%-s%kE%ED-A%
•  !^+'%TJ+'%Ia%-Ap)%EJ(%
•  tr@%u(p%@hv+'%@w%+r(%@AxE%&y23%
MzK%IAJ+'%ka(%-b(%Tv+%A`{-%I|C%
q*P-$X(*$.S>{$@|vi$}$]*a $b^+$(z+$R"+$viK$
6t%$2!v$'(!#UG$4wG$_*'($,!3$:?%AKR(%u(p%CAd+'%fKr+%-s%A`{-%
@J-%Y}+'%CA}%-Ap)%EJ(%CA}%@A(~-%•KL(%Y€+'%
•  g•‚j••>%Oj/fK'/@G/+0%144/0%8966Q%
•  2WWg24"•%O2CKƒ/f/+0%1„/0%899\Q%
•  2!…2"‚23"%!4>4%;5%OgKM/G`ƒ/f/+0%1„/0%899\Q%
•  g†$‡‚6%Oj/G[ƒ/f/+0%1„/0%8966Q%

•  •"!••>%O„KE[•K'/@G/+0%144/0%899UQ%%
6t%$2!v$'(!#UG$4wG$_*'($,!3$C?$
•  j/fK'/@G/+l%-Ah/%kr+%A]+A%
•  2WWg24"•%8l%Yˆ+'%•DK%ZzE%M‰%-Ap)%EJ(%u(J%EŠ-%
•  2!…2"%8‚!4>4%:6%
@.*#J-$(A+$57$@|vi$E$*S#$(*A $5=-*$(T>$